Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dolutegravir vs Elvitegravir/Cobicistat After Cessation in Healthy Volunteers
NCT02219217Phase 1Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Oct 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by St Stephen's AIDS Trust. Primary endpoint: Steady state plasma concentrations of dolutegravir and elvitegravir/cobicistat after drug intake cessation at 216 hours. Started Oct 2014; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02219217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219217.